Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products
Version of Record online: 16 JUN 2009
© 2009 The Author(s). Journal compilation © 2009 International Society of Blood Transfusion
Volume 97, Issue 3, pages 207–210, October 2009
How to Cite
Ward, H. J. T., MacKenzie, J. M., Llewelyn, C. A., Knight, R. S. G., Hewitt, P. E., Connor, N., Molesworth, A. and Will, R. G. (2009), Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. Vox Sanguinis, 97: 207–210. doi: 10.1111/j.1423-0410.2009.01205.x
- Issue online: 24 SEP 2009
- Version of Record online: 16 JUN 2009
- Received: 26 April 2009, revised 19 May 2009, accepted 20 May 2009, published online 16 June 2009
- fractionated plasma products;
- public health;
Background The risk to public health of onward transmission of variant Creutzfeldt–Jakob disease (vCJD) via blood transfusion and plasma product administration is of on-going concern, particularly with the recent reported detection of abnormal prion protein in a person with haemophilia.
Objectives To describe the history of fractionated plasma product exposure in clinical cases of vCJD in the UK.
Methods Through examination of records held at the National CJD Surveillance Unit (from relatives, general practices and hospitals).
Results Nine out of 168 UK vCJD cases had a history of receipt of fractionated plasma products on 12 different occasions (1 pre-vCJD risk in 1970, the remaining between 1989–1998). According to the UK CJD Incident Panel risk assessment criteria, 11 were low-risk products and one was low or medium risk.
Conclusion It is unlikely that any of the UK vCJD clinical cases to date were infected through exposure to fractionated plasma products. However, the possibility that such transmission may result in vCJD cases in the future cannot be excluded.